Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcellx

REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Gilead Sciences stock (NASDAQ NASDAQ : GILD) trades at $65 per share, about 11% below the level seen in December 2021. GILD stock was trading at around $62 in early June 2022, just before the Fed started increasing rates, and is still close to that level, compared to a substantial 37% gain for the S&P 500 during this period.

Will Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75?

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma. New Data Provide Detail on Trodelv.

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

Bumble

Coursera

Caesars Entertainment

Five Below

Papa John's

ZipRecruiter

If you really want to maximize your return potential, then acquiring stocks near 52-week lows could present a viable opportunity. Stated simply, it's a way to practice buying low and selling high.

Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back

Biohaven Pharmaceutical Hld

Moderna

Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.

Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar

British American Tobacco

Unilever

Throughout my journey as an investor, I've learned that some of my most profitable picks stem from purchasing quality businesses when their share prices have been battered. A useful starting point for identifying such opportunities is filtering for stocks near their 52-week lows.

3 Dividend Stocks to Buy at a 52-Week Low in April

Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy o.

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Chris Schott - JPMorgan Daina Graybosch - Leerink Partners Umer Raffat - Evercore ISI Tyler Van Buren - TD Cowen Geoff Meacham - Bank of America Michael Yee - Jefferies Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Mohit Bansal - Wells Fargo Simon Baker - Redburn Atlantic Brian Abrams - RBC Capital Markets Terence Flynn - Morgan Stanley Carter Gould - Barclays Operator Good afternoon, everyone, and welcome to Gilead's First Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today.

Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago.

Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates

The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.

Gilead Beats Earnings Expectations After Rocky Quarter

Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. And Gilead stock jumped in late trades Thursday.

Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again

Gilead Sciences Inc.'s stock rose 0.8% in after-hours trading Thursday, after the drug company's adjusted first-quarter profit was narrower than expected.

Gilead's quarterly loss is narrower than expected

Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales.

Gilead posts quarterly loss, revenue rises 5%

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a reg.

Gilead Sciences Announces First Quarter 2024 Financial Results

AbbVie

Bristol-Myers

Merck

Sanofi

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Cisco Systems

ON Semiconductor

Among Wall Street stocks, some of the best opportunities can be found in reliable companies trading at a discount. With such undervalued stocks, investors get a strong foundation for their portfolio along with potential for positive returns.

Undervalued Icons: 3 Household Names Trading at Steep Discounts

Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics

Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

UnitedHealth Group

Verve Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.

News for Gilead Sciences Stock (GILD)